Medicexchange.com News

Gene therapy is secure for grave form of brain cancer, even when merged with radiation therapy – clinical trial report states

 

The innovative treatment makes use of an adenovirus vector (AdV-tk); it is applied in the operating room, after taking off brain tumors, viz. glioblastoma multiforme. (Courtesy: Ohio State University Comprehensive Cancer Center; Journal of Clinical Oncology)

The treatment might even incite reaction against the tumor; this is first ever approach of gene therapy with radiation for newly identified glioblastoma; grave concerns related to toxicity were there with combination of both the treatments, but the findings are positive.

About 13,000 die annually due to Glioblastomas in the U.S.; average survival of grave/most common Glioblastoma multiforme is 15 months post diagnosis.

Due to typical migration of cancer cells to neighboring brain tissues, tumors recur frequently; the study evaluates immunogene therapy, which is devised to kill undiscovered cancer cells, and impede recurrence. (vide: Oncology)

About 10 patients with glioblastoma multiforme, and 2 with anaplastic astrocytoma involved in the study; the routine follows – after removal of tumor, the tumor bed is injected with 1 milliliter of a solution comprising the AdV-tk vector; it carries gene from herpes simplex virus, for thymidine kinase; infected cells with the vector start making the enzyme. Patients take anti-herpes virus drug for about 14 days; within cancer cells – herpes thymidine kinase transform valacyclovir into DNA building blocks.

Radiotherapy begins midway through the pattern of valacyclovir (drug); DNA in the infected cells get damaged by radiation – it then tries to mend it, through toxic valacyclovir building blocks.

More to enhanced survival, studies disclosed a considerable rise in amount of T lymphocytes in the tumors; this indicates that gene therapy incited an immune reaction against tumor. In cancer immunogene therapy, cancer cells are genetically manipulated to incite a immune reaction against the tumor.

With supportive results from phase 2 efficacy trial, next step will be to equate the therapy with existent standard of care, researchers conclude.